RENAL PROTECTIVE COMPARISON BETWEEN SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS VERSUS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS: A SYSTEMATIC REVIEW
Main Article Content
Keywords
Abstract
In the realm of diabetes, the therapeutic panorama has changed for chronic kidney disease with the emergence of SGLT2 inhibitors and GLP-1.
This research aims to conduct a comprehensive comparative analysis of the renoprotective effects of SGLT2 inhibitors and GLP-1 RAs in individuals with T2DM and renal complications and to provide comprehensive awareness of the mechanisms, efficacy comparison, and practical advice on visionary care for the management of CKD with T2DM.
2093 records from 2013 to 2023 were identified electronically using Google Scholar, MEDLINE, PubMed, and ScienceDirect databases. Grey material was also searched. RCTs and meta-analyses reporting renal composite outcomes, such as changes in eGFR, urinary albumin progression, and ERSD results after GLP-1 RAs and SGLT-2 inhibitors therapy in T2DM with CKD patients were included. HRs, RR, and 95% CI were calculated. Quality assessment was done using the AMSTAR-2 checklist.
The prevalence of renal composite outcomes and albuminuria was (33% to 36%) and (38% to 42%) in SGLT2i-treated patients respectively, compared to GLP-1RAs-treated patients (14% to 24%) and (10% to 20%) proportionately. The annual decline in eGFR (34% versus 15%) and UACR changes (38% versus 20%) was noted between the two groups. Progression to ESRD and serum creatinine also differed significantly in SGLT2i-treated patients than in GLP-1RA-treated patients.
The Preliminary findings from the data analysis indicate that both drug classes exhibit positive effects on renal function improvement, but SGLT2 inhibitors exhibit superiority over GLP-1 receptor agonists regarding renal outcome in T2DM patients with CKD. Further research is required to validate both drugs’ efficacy in this population.
References
1. Alicic, R.Z., Johson, E., Tuttle, K.R. et al. (2018). `SGLT2 inhibition for the prevention and treatment of diabetic kidney disease: a review’, American Journal of Kidney Diseases, 72(2), pp.267-277. Available at: https://doi.org/10.1053/j.ajkd.2018.03.022 (Access on May 18, 2023)
2. Ali, M.U., Mancini, G.B., Fitzpatrick, D. et al. (2022). `The effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists on cardiorenal outcomes: systematic review and meta-analysis’, Canadian Journal of Cardiology, 38(8), pp.1201-1210. Available at: https://doi.org/10.1016/j.cjca.2022.05.011. (Access on May 12, 2023)
3. American Diabetes Association. (2021). `Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2021’, Diabetes care, 44(Supplement_1), pp. S111-S124. Available at: https://doi.org/10.2337/dc21-S009. (Access on May 18, 2023)
4. Bae, J.H., et al. (2019). `Effects of SGLT2 inhibitors on renal outcomes in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials’, Scientific reports, 9(1), p.13009. Available at: https://www.nature.com/articles/s41598-019-49525-y (Access on June 03, 2023)
5. Bethel MA., et al. (2020). `Microvascular and cardiovascular outcomes according to renal function in patients treated with once-weekly exenatide: insights from the EXSCEL trial’, Diabetes Care 2020;43:446–452. Available at: https://doi.org/10.2337/dc19-1065 (Access on May 18, 2023)
6. Brown, E., Heerspink, H.J., Cuthbertson, D.J. et al (2021). `SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications’, The Lancet, 398(10296), pp.262-276. Available at: https://doi.org/10.1016/S0140-6736(21)00536-5 (Access on June 03, 2023)
7. Berndt, J., Ooi, S.L. and Pak, S.C. (2021). `What Is the Mechanism Driving the Reduction of Cardiovascular Events from GLP-1 Receptor Agonists? —A Mini Review’, Molecules, 26(16), p.4822. Available at: https://doi.org/10.3390/molecules26164822 (Access on May 12, 2023)
8. Cannon, CP. et al. (2018). `VERTIS-CV trial. Design and baseline characteristics of the evaluation of Ertugliflozin efficacy and Safety Cardiovascular outcomes trial (VERTIS-CV)’, Am Heart J. 2018 Dec;206:11-23. Available at: https://doi.org/10.1016/j.ahj.2018.08.016. (Access on May 18, 2023)
9. Cao, H., Liu, T., and Wang, Li. (2022). `Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta‐analysis’, Diabetes, Obesity, and Metabolism, 24(8), pp.1448-1457. Available at: https://doi.org/10.1111/dom.14702 (Access on May 18, 2023)
10. Caruso, I., et al. 2022. `Cardiovascular and renal effectiveness of GLP-1 receptor agonists vs. other glucose-lowering drugs in type 2 diabetes: a systematic review and meta-analysis of real-world studies’, Metabolites, 12(2), p.183. Available at: https://doi.org/10.3390/metabo12020183. (Access on May 18, 2023)
11. CDC (Centres for Disease Control and Prevention). (2021). `Causes of renal disease’. Available online at: https://www.cdc.gov/kiddneydisease/CKD-2021. (Access on June 03, 2023)
12. Charlton, A., Garzarella, J., Jandeleit-Dahm, K. et.al. (2020). `Oxidative stress and inflammation in renal and cardiovascular complications of diabetes’, Biology, 10(1), p.18. Available at: https://doi.org/10.3390/biology10010018. (Access on June 06, 2023)
13. Cherney, D.Z., Udell, JA., and Drucker, DJ. (2021). `Cardiorenal mechanisms of action of GLP-1 receptor agonists and SGLT2 inhibitors’, Med, 2(11), pp.1203-1230. Available at: https://www.cell.com/med/pdf/S2666-6340(21)00344-5.pdf.(Access on June 06, 2023)
14. Cherney, D.Z., Zinman, B., Inzucchi, SE. et al. (2017). `Effects of empagliflozin on the UACR in patients with T2DM and established CVD: an exploratory analysis from the EMPA-REG OUTCOME trial’, The Lancet Diabetes & Endocrinology, 5(8), pp.610-621. Available at: https://doi.org/10.1016/S2213-8587(17)30182-1 (Access on June 06, 2023)
15. de Boer., et al. (2020). `Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment’, Kidney International, 98(4), pp.839-848. Available at: https://doi.org/10.1016/j.kint.2020.06.024 (Access on June 03, 2023)
16. DeFronzo, R.A. (2017). `Combination therapy with GLP‐1 receptor agonist and SGLT2 inhibitor’, Diabetes, Obesity and Metabolism, 19(10), pp.1353-1362. Available at: https://doi.org/10.1111/dom.12982 (Access on June 06, 2023)
17. Diallo, A., Carlos-Bolumbu, M., and Renard, PE. (2023). `Larger effect size in composite kidney outcomes than in major cardiovascular events associated with SGLT2 inhibitors compared with GLP‐1 RAs: A pooled analysis of type 2 diabetes trials’, Diabetes, Obesity and Metabolism, 25(1), pp.166-176. Available at: https://doi.org/10.1111/dom.14859 (Access on May 12, 2023)
18. Duan, X.Y., Liu, S.Y., and Yin, D. (2021). `Comparative efficacy of 5 sodium-glucose cotransporters 2 inhibitors and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: a network meta-analysis based on cardiovascular or renal outcome trials’, Medicine, 100(30). Available at: https://doi.org/10.1097%2FMD.0000000000026431 (Access on May 18, 2023)
19. Duo, Y., Gao, J., Yuan, T. et al. (2023). `Effect of sodium‐glucose cotransporter 2 inhibitors on the rate of decline in kidney function: A systematic review and meta‐analysis’, Journal of Diabetes, 15(1), pp.58-70. Available at: https://doi.org/10.1111/1753-0407.13348 (Access on May 23, 2023)
20. Fei, Y., Tsoi, M.F., and Cheung, B. (2019). `Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis’, Cardiovascular diabetology, 18(1), pp.1-13. Available at: https://cardiab.biomedcentral.com/articles/10.1186/s12933-019-0916-z (Access on May 23, 2023)
21. Fitchett, D., Inzucchi, SE., Cannon, CP. et. Al. (2019). `Empagliflozin reduced mortality and hospitalization for HF across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial’, Circulation, 139(11), pp.1384-1395. Available at: https://doi.org/10.1161/CIRCULATIONAHA.118.037778 (Access on May 23, 2023)
22. Fotheringham, A.K., Gallo, LA., Borg, DJ. et al. (2022). `Advanced glycation end products (AGEs) and chronic kidney disease: does the modern diet AGE the kidney’, Nutrients, 14(13), p.2675. Available at: https://doi.org/10.3390/nu14132675 (Access on June 06, 2023)
23. Georgianos, P.I., Vaios, V., Roumeliotis, S. et al. (2022). `Evidence for cardiorenal protection with SGLT-2 inhibitors and GLP-1 receptor agonists in patients with diabetic kidney disease’, Journal of Personalized Medicine, 12(2), p.223. Available at: https://doi.org/10.3390/jpm12020223 (Access on June 06, 2023)
24. Gerstein, H.C., Colhoun, M., Dagenais, G. et al. (2019). `Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomized placebo-controlled trial’, The Lancet, 394(10193), pp.121-130. Available at: https://doi.org/10.1016/S0140-6736(19)31149-3 (Access on May 23, 2023)
25. Ghosal, S. and Sinha, B. (2023). `Assessing the Effects of Modern Renoprotective Agents in Preventing Progression of Renal Composite Outcomes in Patients with Type 2 Diabetes: A Network Meta-analysis’, Diabetes Therapy, 14(2), pp.415-424. Available at: https://doi.org/10.1007/s13300-022-01359-0 (Access on May 23, 2023)
26. Giugliano, D., Longo, M., Signoriello, S. et al. (2022). `The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs’, Cardiovascular Diabetology, 21(1), p.42. Available at: https://doi.org//10.1186/s12933-022-01474-z (Access on May 23, 2023)
27. Grant, R.L. (2014). `Converting an odds ratio to a range of plausible relative risks for better communication of research findings’, Bmj, 348. Available at: https://doi.org/10.1136/bmj.f7450 (Access on June 06, 2023)
28. Gómez-Huelgas, R., Sanz-Canovas, J., Cobos-Palacis, L. et al. (2022). `GLP-1 receptor agonists and SGLT 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect’, European Journal of Internal Medicine, 96, pp.26-33. Available at: https://doi.org/10.1016/j.ejim.2021.11.008 (Access on May 18, 2023)
29. Heerspink, H.J.L. and Stefánsson, B.V. (2020). `Dapagliflozin in patients with chronic kidney disease’, N Engl J Med, 383, pp.1436-1446. Available at: https://doi.org/ 10.1056/NEJMoa2024816 (Access on May 18, 2023)
30. Heerspink, H.J., Desai, M., Jardine, M. et al. (2017). `Canagliflozin slows the progression of renal function decline independently of glycemic effects’, Journal of the American Society of Nephrology: JASN, 28(1), p.368. Available at: https://doi.org/10.1681/ASN.2016030278 (Access on May 23, 2023)
31. Herrington, W., Presiss, D., Haynes, R. et al. (2018). `The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study’, Clinical kidney journal, 11(6), pp.749-761. Available at: https://doi.org/10.1093/ckj/sfy090 (Access on June 11, 2023)
32. Holman, R., Sourji, H., and Califf, R. (2014). ‘Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes’, The Lancet 383, no. 9933 (2014): 2008-2017. Available at: https://doi.org/10.1016/S0140-6736(14)60794-7
33. Hornberger, B. and Rangu, S. (2020). `Designing inclusion and exclusion criteria’. Available online at: https://repository.upenn.edu/cgi/viewcontent.cgi?article=1000&context=crp (Access on June 11, 2023)
34. International Diabetes Federation. (2020). `Diabetes facts & figures’. Available online at: https://idf.org/aboutdiabetes/what-is-diabetes/ facts-figures.html (Access on June 11, 2023)
35. Jager, K.J., Kovesdy, C., Langham, R. et al. (2019). `A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases’, Nephrology Dialysis Transplantation, 34(11), pp.1803-1805. Available at: https://doi.org/10.1093/ndt/gfz174 (Access on June 14, 2023)
36. Jaikumkao, K., et al. 2017. `The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes’, Biomedicine & Pharmacotherapy, 94, pp.176-187. Available at: https://doi.org/10.1093/ndt/gfz174 (Access on June 11, 2023)
37. Karagiannis, T., Tsapas, A., Athanasiadou, E. et al. (2021). `GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis’, Diabetes Clinical Practice. 2021 Apr; 174:108737. Available at: https://doi.org/10.1016/j.diabres.2021.108737. PMID: 33705820. (Access on May 23, 2023)
38. Kanie, T., Mizuno, A., Takaoka, Y. et al. (2021). `DPP4 inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors for people with cardiovascular disease: a network meta‐analysis’, Cochrane Database of Systematic Reviews. Available at: https://doi.org/10.1002/14651858.CD013650.pub2 (Access on June 03, 2023)
39. Kawai, Y., Uneda, K., Yamada, T. et al. (2022). `Comparison of effects of SGLT-2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in T2DM patients with/without albuminuria: a systematic review and network meta-analysis’, Diabetes Research and Clinical Practice, 183, p.109146. Available at: https://doi.org/10.1016/j.diabres.2021.109146 (Access on May 23, 2023)
40. KDIGO (2022). `Clinical Practice Guidelines for Diabetes Management in CKD’, Kidney Int. 2022; 102(4S):S1-S123. Available at: https://doi.org/10.1016/j.kint.2022.06.008 (Access on June 03, 2023)
41. Yau, K., Dharia, A., Alrowiyti, I. et al. (2022). `Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations’, Kidney international reports, 7(7), pp.1463-1476. Available at: https://doi.org/10.1016/j.ekir.2022.04.094 (Access on June 14, 2023)
42. Khoury, C.C., Chen, S., and Ziyadeh, F.N. (2020). `Pathophysiology of diabetic nephropathy’, Chronic Renal Disease (pp. 279-296). Available at: https://doi.org/10.1016/B978-0-12-815876-0.00019-X (Access on June 03, 2023)
43. Kluger, A.Y., Tecson, K., Lee, A.Y. et al. (2019). ‘Class effects of SGLT2 inhibitors on cardiorenal outcomes’, Cardiovascular diabetology, 18, pp.1-13. Available at: https://doi.org/10.1186/s12933-019-0903-4 (Access on June 11, 2023)
44. Kristensen, S.L., Roth, R., Jhund, P.S. et al. (2019). `Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials’, The Lancet Diabetes & Endocrinology, 7(10), pp.776-785. Available at: https://doi.org/10.1016/S2213-8587(19)30249-9 (Access on June 03, 2023)
45. Fu, H., Liu, S., Bastacky, S.I. et al. (2019). `Diabetic kidney diseases revisited: A new perspective for a new era’, Molecular metabolism, 30, pp.250-263. Available at: https://doi.org/10.1016/j.molmet.2019.10.005 (Access on June 03, 2023)
46. Li, J., Neal, B., Perkovoc, V. et al. (2020). `Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes’, Kidney International, 98(3), pp.769-777. Available at: https://doi.org/10.1016/j.kint.2020.04.051 (Access on May 23, 2023)
47. Li, X., Song, Y., Guo, T. et al. (2022). `Effect of glucagon-like peptide 1 receptor agonists on the renal protection in patients with type 2 diabetes: A systematic review and meta-analysis’, Diabetes & Metabolism, p.101366. Available at: https://doi.org/10.1016/j.diabet.2022.101366 (Access on May 23, 2023)
48. Lo, C., Toyama, T., Wang, Y. et al. (2018). `Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease’, Cochrane database of systematic reviews. Available at: https://doi.org/10.1002/14651858.CD011798.pub2 (Access on June 03, 2023)
49. Maddaloni, E., Cavallari I., La Porta, Y. et al. (2023). `Impact of baseline kidney function on the effects of SGLT2 inhibitors on kidney and HF: A systematic review and meta‐analysis of randomized controlled trials’, Diabetes, Obesity, and Metabolism, 25(5), pp.1341-1350. Available at: https://doi.org/10.1111/dom.14986 (Access on May 12, 2023)
50. Mann JFE, Ørsted DD., Brown-Frandsen, K. et al. (2017). `Liraglutide and renal outcomes in type 2 diabetes’, New England Journal of Medicine. 2017;377(9):839-848`. Available at: https://doi.org/10.1056/NEJMoa1616011. PMID: 28854085. (Access on May 12, 2023)
51. Marso, S.P., Daniels, G.H., Brown-Frandsen, K. et al. (2016). `Liraglutide and cardiovascular outcomes in type 2 diabetes’, New England Journal of Medicine, 375(4), pp.311-322. Available at: https://doi.org/10.1056/NEJMoa1603827 (Access at May 12, 2023)
52. Marso, S.P., Stephen, C. B., Consoli, A. et al. (2016). `Semaglutide and cardiovascular outcomes in patients with type 2 diabetes’, New England Journal of Medicine, 375(19), pp.1834-1844. Available at: https://doi.org/10.1056/NEJMoa1607141 (Access on May 12, 2023)
53. Margonato, D., Galati, G., Mazzetti, S. et al. (2021). `Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors’, Heart failure reviews, 26, pp.337-345. Available at: https://doi.org/10.1007/s10741-020-10024-2 (Access on June 14, 2023)
54. McGuire, D.K., Zinman, B., Inzucchi, S. et al. (2020). `Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial’, The Lancet Diabetes & Endocrinology, 8(12), pp.949-959. Available at: https://doi.org/10.1016/S2213-8587(20)30344-2 (Access on May 12, 2023)
55. McGuire, D.K., D’Alessio, D., Nicholls, S.J. et al. (2022). `Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes’, Cardiovascular Diabetology, 21(1), pp.1-9. Available at: https://doi.org/10.1186/s12933-022-01601-w (Access on May 12, 2023)
56. Milder, T.Y., Stoker, S., Baysari, M. et al. (2021). `Prescribing of SGLT2 inhibitors in primary care: A qualitative study of General Practitioners and Endocrinologists’, Diabetes Research and Clinical Practice, 180, p.109036. Available at: https://doi.org/10.1016/j.diabres.2021.109036 (Access on June 14, 2023)
57. Mima, A. (2022). `A narrative review of diabetic kidney disease: previous and current evidence-based therapeutic approaches’, Advances in therapy, 39(8), pp.3488-3500. Available at: https://doi.org/10.1007/s12325-022-02223-0 (Access on May 07, 2023)
58. Mosenzon, O., Wiviott, S.D., Heerspink, H.J.L et al. (2021). `The effect of dapagliflozin on albuminuria in DECLARE-TIMI 58’, Diabetes Care, 44(8), pp.1805-1815. https://doi.org/10.2337/dc21-0076 (Access on June 14, 2023)
59. Mosterd, C.M., Bjornstad, P., and van Raalte. (2020). `Nephroprotective effects of GLP-1 receptor agonists: where do we stand’, Journal of Nephrology, 33, pp.965-975. Available at: https://doi.org/10.1007/s40620-020-00738-9 (Access on June 14, 2023)
60. Nagahisa, T. and Saisho, Y. (2019). `Cardiorenal protection: the potential of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes’, Diabetes Therapy, 10(5), pp.1733-1752. Available at: https://doi.org/10.1007/s13300-019-00680-5 (Access on June 14, 2023)
61. Nagasu, H., Yano, Y., Kanegae, H. et al. (2021). `Kidney outcomes associated with SGLT2 inhibitors versus other glucose-lowering drugs in real-world clinical practice: the Japan chronic kidney disease database’, Diabetes Care, 44(11), pp.2542-2551. Available at: https://doi.org/10.2337/dc21-1081 (Access on May 23, 2023)
62. Nathan, D.M., Buse, J.B., Davidson, M.B. et al. (2009). `Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy’, Diabetes care, 32(1), pp.193-203. Available at: https://doi.org/10.2337/dc08-9025 (Access on June 14, 2023)
63. Nauck, M.A., Meier, J., Mathew, A. et al. (2017). `Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors’, Circulation, 136(9), pp.849-870. Available at: https://doi.org/10.1161/CIRCULATIONAHA.117.028136 (Access on June 14, 2023)
64. Neuen, B.L., Young, T., Heerspink, H. J.L. et al. (2019). `SGLT2 inhibitors for the prevention of kidney failure in patients with T2DM: a systematic review and meta-analysis’, The Lancet Diabetes & Endocrinology, 7(11), pp.845-854. Available at: https://doi.org/10.1016/S2213-8587(19)30256-6 (Access on May 07, 2023)
65. Nguyen, B.N., Nguyen, Le., Mital, S. et al. (2023). `Comparative Efficacy of SGL2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease and Type 2 Diabetes: A Systematic Review and Network Meta‐Analysis’, Diabetes, Obesity and Metabolism’. Available at: https://doi.org/10.1111/dom.15009 (Access on May 12, 2023)
66. Neal, B., Perkovic, V., Mahaffey, K.W. et al. (2017). `Canagliflozin and cardiovascular and renal events in T2DM’, New England Journal of Medicine, 377(7), pp.644-657’. Available at: https://doi.org/10.1056/NEJMoa1611925. (Access on May 07, 2023)
67. Ninčević, V., Omanović Kolarić, T., Roguljić, H. et al. (2019). `Renal benefits of SGLT 2 inhibitors and GLP-1 receptor agonists: evidence supporting a paradigm shift in the medical management of type 2 diabetes’, International Journal of Molecular Sciences, 20(23), p.5831.Available at: https://doi.org/10.3390/ijms20235831
68. Packer, M., Butler, J., Filippatos, G. S. et al. (2019). `Evaluation of the effect of SGLT2 2 inhibitors with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial’, European Journal of heart failure, 21(10), pp.1270-1278’. Available at: https://doi.org/10.1002/ejhf.1536 (Access on May 12, 2023)
69. Palmer, S.C., Tendal, B., Mustafa, R.A. et al. (2021). `SGLT-2 inhibitors and GLP-1 receptor agonists for type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials’, The BMJ 372’. Available at: https://doi.org/10.1136/bmj.m4573 (Access on May 07, 2023)
70. Patoulias, D., Papadopoulos, C., Karagiannis, A. et al. (2022). `Meta-analysis assessing the impact of previous heart failure and chronic kidney disease on the cardiovascular efficacy of glucagon-like peptide-1 receptor agonists’, American Journal of Cardiology, 167, pp.165-167. Available at: https://doi.org/10.1016/j.amjcard.2021.12.040 (Access on June 15, 2023)
71. Perkovic, V., Jardine, M.J., Neal, B. et al. (2019). `Canagliflozin and renal outcomes in type 2 diabetes and nephropathy’, New England Journal of Medicine, 380(24), pp.2295-2306. Available at: https://doi.org/10.1056/NEJMoa1811744. (Access on May 07, 2023)
72. Porzsolt, F., Wiedemann, F., and Becker, S.I. et al. (2019). `Inclusion & exclusion criteria and the problem of describing homogeneity of the study population in clinical trials’, BMJ evidence-based medicine, 24(3), pp.92-94. Available at: http://dx.doi.org/10.1136/bmjebm-2018-111115 (Access on May 07, 2023)
73. Qiu M., Liang, D., Xu-Bin, W. et al. (2021). `Comparative efficacy of GLP-1 receptor agonists and SGLT2 Inhibitors for prevention of major adverse cardiovascular events in T2DM’, A network meta-analysis; Journal of Cardiovascular Pharmacology. 2021 Jan 1;77(1):34-37`. Available at: doi:10.1097/FJC.00000000000916. PMID: 33136765. (Access on May 07, 2023)
74. Rangaswami, J., Bhalla, V., de Boer, I. H. et al. (2020). `Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American Heart Association’, Circulation, 142(17), pp. e265-e286`. Available at: https://doi.org/10.1161/CIR.0000000000000920. (Access on March 30, 2023)
75. Ravindran, S. and Munusamy, S., (2022). `Reno-protective mechanisms of SGLT2 inhibitors against the progression of diabetic kidney disease’, Journal of cellular physiology, 237(2), pp.1182-1205. Available at: https://doi.org/10.1002/jcp.30621 (Access on March 30, 2023)
76. Rossing, P., Caramori, M.L., Chan, J.C.N. et al. (2022). `Executive summary of the KDIGO 2022. Clinical practice guideline for diabetes management in CKD: an update based on rapidly emerging new evidence’, Kidney International, 102(5), pp.990-999. Available at: https://doi.org/10.1016/j.kint.2022.06.013 (Access on June 14, 2023)
77. Sarafidis, P., Ferro, C.J., Morales, E. et al. (2019). `SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA’, Nephrology Dialysis Transplantation, 34(2), pp.208-230. Available at: https://doi.org/10.1093/ndt/gfy407 (Access on June 14, 2023)
78. Sattar N., Lee, M., Kristensen, S.L. et al. (2021). `Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with T2DM: a systematic review and meta-analysis of RCTs’, Lancet Diabetes Endocrinology 2021;9:653–662. Available at: https://doi.org/10.1016/S2213-8587(21)00203-5 (Access on May 07, 2023)
79. Scheen, A.J. (2018). “Cardiovascular outcome studies in type 2 diabetes: comparison between SGLT2 inhibitors and GLP-1 receptor agonists’, Diabetes Research and Clinical Practice, 143, pp.88-100. Available at: https://doi.org/10.1016/j.diabres.2018.06.008 (Access on May 07, 2023)
80. Scheen, A.J. (2019). “Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes’, Diabetes & metabolism, 45(2), pp.110-121. Available at: https://doi.org/10.1016/j.diabet.2018.10.003 (Access on June 15, 2023)
81. Shaman, A.M., Bain. S., Bakris. G. et al. (2022). `Effect of the glucagon-like peptide-1 receptor agonists Semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER’, Circulation, 145(8), pp.575-585. Available at: https://doi.org/10.1161/CIRCULATIONAHA.121.055459 (Access on June 15, 2023)
82. Shami, D., Sousou, J., Batarseh, E. et al. (2023). `The roles of Glucagon-Like Peptide 1 (GLP-1) receptor agonists and Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in decreasing the occurrence of adverse cardiorenal events in patients with Type 2 Diabetes’, Cureus, 15(1). Available at: https://doi.org/10.7759/cureus.33484 (Access on May 07, 2023)
83. Shepard, B.D. and Ecelbarger, C.M. (2022). `SGLT2 inhibitors and GLP-1 RAs: newer therapies in whole-body glucose stabilization’, Seminars in Nephrology (Vol. 41, No. 4, pp. 331-348). WB Saunders. Available at: https://doi.org/10.1016/j.semnephrol.2021.06.005 (Access on June 15, 2023)
84. Sloan, L.A. (2019). `Review of glucagon‐like peptide‐1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects’, Journal of diabetes, 11(12), pp.938-948. Available at: https://doi.org/10.1111/1753-0407.12969 (Access on March 30, 2023)
85. Thomas, M.C. and Cherney, D.Z. (2018). `The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure’, Diabetologia, 61, pp.2098-2107. Available at: https://doi.org/10.1007/s00125-018-4669-0 (Access on June 15, 2023)
86. Tuttle KR., Brosius, F., Cavender, M. et al. (2021). `SGLT2 Inhibition for CKD and cardiovascular disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation’, Diabetes. 2021 Jan;70(1):1-16. Available at: https://doi 10.2337/dbi20-0040.PMID: 33106255 (Access on May 07, 2023)
87. Tuttle KR., Lakshmanan, M., Rayner, B. et al. (2018). `Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7)’, Lancet Diabetes Endocrinol. 2018 Apr;6(4):605-617. Available at: https://doi: 10.1016/S2213-8587(18)30051-2. PMID: 29502976. (Access on March 30, 2023)
88. Uneda, K., Kawai, Y., Yamada, T. et al. (2022). `Japanese traditional Kampo medicine bofutsushosan improves body mass index in participants with obesity: A systematic review and meta-analysis’, Plos one, 17(4), p. e0266917. Available at: https://doi.org/10.1371/journal.pone.0266917(Access on March 30, 2023)
89. Vallon, V. and Thomson, S.C. (2017). `Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition’, Diabetologia, 60(2), pp.215-225. Available at: https://doi.org/10.1007/s00125-016-4157-3 (Access on June 15, 2023)
90. van Baar, M.J., Van Ruiten, C., Muskiet, M. et al. (2018). `SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in T2DM management’, Diabetes care, 41(8), pp.1543-1556. Available at: https://doi.org/10.2337/dc18-0588 (Access on March 30, 2023)
91. Wanner C., Inzucchi, S. E., Lachin, J.M. et al. (2016). `Empagliflozin and progression of kidney disease in Type 2 Diabetes’, N Engl J Med. 2016 Jul 28; 375(4):323-34. Available at: https://doi.org/10.1056/NEJMoa1515920. PMID: 27299675. (Access on May 07, 2023)
92. Wheeler, D.C., Toto, R.D., Stefansson, B.V. et al. (2020). `The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics’, Nephrology Dialysis Transplantation, 35(10), pp.1700-1711. Available at: https://doi.org/10.1016/j.kint.2021.03.033 (Access on May 07, 2023)
93. Wei XB.,Wei, W, Ding, L. et al. (2021). `Comparison of the effects of 10 GLP-1 RAs and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in T2DM: A network meta-analysis of large randomized trials’, Prim Care Diabetes. 2021. Apr;15(2): 208-211. Available at: https://doi: 10.1016/j.pcd.2020.08.017. (Access on March 13, 2023)
94. Williams, D.M., Nawaz, A. and Evans, M. et al. (2020). `Renal outcomes in type 2 diabetes. A review of cardiovascular and renal outcome trials’, Diabetes Therapy, 11(2), pp.369-386. Available at: https://doi.org/10.1007/s13300-019-00747-3 (Access on May 07, 2023)
95. Wiviott, S.D., Raz, Itamar., Bonaca, M.P. et al. (2019). `Dapagliflozin and cardiovascular outcomes in type 2 diabetes’, New England Journal of Medicine, 380(4), pp.347-357. Available at: https//doi.org/10.1056/NEJMoa1812389 (Access on March 30, 2023)
96. Yamada, T., Wakabayashi, M., Bhalla, A. et al. (2021). `Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis’, Cardiovascular diabetology, 20(1), pp.1-13. Available at: https://doi.org/10.1186/s12933-020-01197-z (Access on March 13, 2023)
97. Yang, S., He, W., Zhao, Lu. (2022). `Association between use of SGLT2 inhibitors, GLP-1 receptor agonists, and dipeptidyl peptidase 4 inhibitors with kidney outcomes in patients with type 2 diabetes: A systematic review and network meta-analysis’, Plos, one, 17(4), p. e0267025. Available at: https://doi.org/10.1371/journal.pone.0267025 (Access on June 15, 2023)
98. Yang, Q., Lang, Y., Yang, W. et al. (2023). `Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: a systematic review and network meta-analysis of randomized controlled trials’, Diabetes Research and Clinical Practice, p.110592. Available at: https://doi.org/10.1016/j.diabres.2023.110592 (Access on May 07, 2023)
99. Zelniker, T.A., Wiviott, S.D., Raz, I. et al. (2019). `Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus: systematic review and meta-analysis of cardiovascular outcomes trials’, Circulation, 139(17), pp.2022-2031. Available at: https://doi.org/10.1161/CIRCULATIONAHA.118.038868 (Access on March 13, 2023)
100. Zelniker, T.A., Wiviott, S.D., Raz, I. et al. (2019). `SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials’, The Lancet, 393(10166), pp.31-39. Available at: https://doi.org/10.1016/S0140-6736(18)32590-X (Access on March 13, 2023)
101. Zhang, Y., Jiang, L., Wang, J. et al. (2022). `Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease’, Cardiovascular diabetology, 21(1), pp.1-23. Available at: https://doi.org/10.1186/s12933-022-01676-5 (Access on March 30, 2023)
102. Zheng, S.L., Roddick, A.J., Aghar-Jaffar, R. et al. (2018). `Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis’, Jama, 319 (15), pp.1580-1591. Available at: https://doi.org/10.1001/jama.2018.3024 (Access on March 13, 2023)
2. Ali, M.U., Mancini, G.B., Fitzpatrick, D. et al. (2022). `The effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists on cardiorenal outcomes: systematic review and meta-analysis’, Canadian Journal of Cardiology, 38(8), pp.1201-1210. Available at: https://doi.org/10.1016/j.cjca.2022.05.011. (Access on May 12, 2023)
3. American Diabetes Association. (2021). `Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2021’, Diabetes care, 44(Supplement_1), pp. S111-S124. Available at: https://doi.org/10.2337/dc21-S009. (Access on May 18, 2023)
4. Bae, J.H., et al. (2019). `Effects of SGLT2 inhibitors on renal outcomes in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials’, Scientific reports, 9(1), p.13009. Available at: https://www.nature.com/articles/s41598-019-49525-y (Access on June 03, 2023)
5. Bethel MA., et al. (2020). `Microvascular and cardiovascular outcomes according to renal function in patients treated with once-weekly exenatide: insights from the EXSCEL trial’, Diabetes Care 2020;43:446–452. Available at: https://doi.org/10.2337/dc19-1065 (Access on May 18, 2023)
6. Brown, E., Heerspink, H.J., Cuthbertson, D.J. et al (2021). `SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications’, The Lancet, 398(10296), pp.262-276. Available at: https://doi.org/10.1016/S0140-6736(21)00536-5 (Access on June 03, 2023)
7. Berndt, J., Ooi, S.L. and Pak, S.C. (2021). `What Is the Mechanism Driving the Reduction of Cardiovascular Events from GLP-1 Receptor Agonists? —A Mini Review’, Molecules, 26(16), p.4822. Available at: https://doi.org/10.3390/molecules26164822 (Access on May 12, 2023)
8. Cannon, CP. et al. (2018). `VERTIS-CV trial. Design and baseline characteristics of the evaluation of Ertugliflozin efficacy and Safety Cardiovascular outcomes trial (VERTIS-CV)’, Am Heart J. 2018 Dec;206:11-23. Available at: https://doi.org/10.1016/j.ahj.2018.08.016. (Access on May 18, 2023)
9. Cao, H., Liu, T., and Wang, Li. (2022). `Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta‐analysis’, Diabetes, Obesity, and Metabolism, 24(8), pp.1448-1457. Available at: https://doi.org/10.1111/dom.14702 (Access on May 18, 2023)
10. Caruso, I., et al. 2022. `Cardiovascular and renal effectiveness of GLP-1 receptor agonists vs. other glucose-lowering drugs in type 2 diabetes: a systematic review and meta-analysis of real-world studies’, Metabolites, 12(2), p.183. Available at: https://doi.org/10.3390/metabo12020183. (Access on May 18, 2023)
11. CDC (Centres for Disease Control and Prevention). (2021). `Causes of renal disease’. Available online at: https://www.cdc.gov/kiddneydisease/CKD-2021. (Access on June 03, 2023)
12. Charlton, A., Garzarella, J., Jandeleit-Dahm, K. et.al. (2020). `Oxidative stress and inflammation in renal and cardiovascular complications of diabetes’, Biology, 10(1), p.18. Available at: https://doi.org/10.3390/biology10010018. (Access on June 06, 2023)
13. Cherney, D.Z., Udell, JA., and Drucker, DJ. (2021). `Cardiorenal mechanisms of action of GLP-1 receptor agonists and SGLT2 inhibitors’, Med, 2(11), pp.1203-1230. Available at: https://www.cell.com/med/pdf/S2666-6340(21)00344-5.pdf.(Access on June 06, 2023)
14. Cherney, D.Z., Zinman, B., Inzucchi, SE. et al. (2017). `Effects of empagliflozin on the UACR in patients with T2DM and established CVD: an exploratory analysis from the EMPA-REG OUTCOME trial’, The Lancet Diabetes & Endocrinology, 5(8), pp.610-621. Available at: https://doi.org/10.1016/S2213-8587(17)30182-1 (Access on June 06, 2023)
15. de Boer., et al. (2020). `Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment’, Kidney International, 98(4), pp.839-848. Available at: https://doi.org/10.1016/j.kint.2020.06.024 (Access on June 03, 2023)
16. DeFronzo, R.A. (2017). `Combination therapy with GLP‐1 receptor agonist and SGLT2 inhibitor’, Diabetes, Obesity and Metabolism, 19(10), pp.1353-1362. Available at: https://doi.org/10.1111/dom.12982 (Access on June 06, 2023)
17. Diallo, A., Carlos-Bolumbu, M., and Renard, PE. (2023). `Larger effect size in composite kidney outcomes than in major cardiovascular events associated with SGLT2 inhibitors compared with GLP‐1 RAs: A pooled analysis of type 2 diabetes trials’, Diabetes, Obesity and Metabolism, 25(1), pp.166-176. Available at: https://doi.org/10.1111/dom.14859 (Access on May 12, 2023)
18. Duan, X.Y., Liu, S.Y., and Yin, D. (2021). `Comparative efficacy of 5 sodium-glucose cotransporters 2 inhibitors and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: a network meta-analysis based on cardiovascular or renal outcome trials’, Medicine, 100(30). Available at: https://doi.org/10.1097%2FMD.0000000000026431 (Access on May 18, 2023)
19. Duo, Y., Gao, J., Yuan, T. et al. (2023). `Effect of sodium‐glucose cotransporter 2 inhibitors on the rate of decline in kidney function: A systematic review and meta‐analysis’, Journal of Diabetes, 15(1), pp.58-70. Available at: https://doi.org/10.1111/1753-0407.13348 (Access on May 23, 2023)
20. Fei, Y., Tsoi, M.F., and Cheung, B. (2019). `Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis’, Cardiovascular diabetology, 18(1), pp.1-13. Available at: https://cardiab.biomedcentral.com/articles/10.1186/s12933-019-0916-z (Access on May 23, 2023)
21. Fitchett, D., Inzucchi, SE., Cannon, CP. et. Al. (2019). `Empagliflozin reduced mortality and hospitalization for HF across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial’, Circulation, 139(11), pp.1384-1395. Available at: https://doi.org/10.1161/CIRCULATIONAHA.118.037778 (Access on May 23, 2023)
22. Fotheringham, A.K., Gallo, LA., Borg, DJ. et al. (2022). `Advanced glycation end products (AGEs) and chronic kidney disease: does the modern diet AGE the kidney’, Nutrients, 14(13), p.2675. Available at: https://doi.org/10.3390/nu14132675 (Access on June 06, 2023)
23. Georgianos, P.I., Vaios, V., Roumeliotis, S. et al. (2022). `Evidence for cardiorenal protection with SGLT-2 inhibitors and GLP-1 receptor agonists in patients with diabetic kidney disease’, Journal of Personalized Medicine, 12(2), p.223. Available at: https://doi.org/10.3390/jpm12020223 (Access on June 06, 2023)
24. Gerstein, H.C., Colhoun, M., Dagenais, G. et al. (2019). `Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomized placebo-controlled trial’, The Lancet, 394(10193), pp.121-130. Available at: https://doi.org/10.1016/S0140-6736(19)31149-3 (Access on May 23, 2023)
25. Ghosal, S. and Sinha, B. (2023). `Assessing the Effects of Modern Renoprotective Agents in Preventing Progression of Renal Composite Outcomes in Patients with Type 2 Diabetes: A Network Meta-analysis’, Diabetes Therapy, 14(2), pp.415-424. Available at: https://doi.org/10.1007/s13300-022-01359-0 (Access on May 23, 2023)
26. Giugliano, D., Longo, M., Signoriello, S. et al. (2022). `The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs’, Cardiovascular Diabetology, 21(1), p.42. Available at: https://doi.org//10.1186/s12933-022-01474-z (Access on May 23, 2023)
27. Grant, R.L. (2014). `Converting an odds ratio to a range of plausible relative risks for better communication of research findings’, Bmj, 348. Available at: https://doi.org/10.1136/bmj.f7450 (Access on June 06, 2023)
28. Gómez-Huelgas, R., Sanz-Canovas, J., Cobos-Palacis, L. et al. (2022). `GLP-1 receptor agonists and SGLT 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect’, European Journal of Internal Medicine, 96, pp.26-33. Available at: https://doi.org/10.1016/j.ejim.2021.11.008 (Access on May 18, 2023)
29. Heerspink, H.J.L. and Stefánsson, B.V. (2020). `Dapagliflozin in patients with chronic kidney disease’, N Engl J Med, 383, pp.1436-1446. Available at: https://doi.org/ 10.1056/NEJMoa2024816 (Access on May 18, 2023)
30. Heerspink, H.J., Desai, M., Jardine, M. et al. (2017). `Canagliflozin slows the progression of renal function decline independently of glycemic effects’, Journal of the American Society of Nephrology: JASN, 28(1), p.368. Available at: https://doi.org/10.1681/ASN.2016030278 (Access on May 23, 2023)
31. Herrington, W., Presiss, D., Haynes, R. et al. (2018). `The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study’, Clinical kidney journal, 11(6), pp.749-761. Available at: https://doi.org/10.1093/ckj/sfy090 (Access on June 11, 2023)
32. Holman, R., Sourji, H., and Califf, R. (2014). ‘Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes’, The Lancet 383, no. 9933 (2014): 2008-2017. Available at: https://doi.org/10.1016/S0140-6736(14)60794-7
33. Hornberger, B. and Rangu, S. (2020). `Designing inclusion and exclusion criteria’. Available online at: https://repository.upenn.edu/cgi/viewcontent.cgi?article=1000&context=crp (Access on June 11, 2023)
34. International Diabetes Federation. (2020). `Diabetes facts & figures’. Available online at: https://idf.org/aboutdiabetes/what-is-diabetes/ facts-figures.html (Access on June 11, 2023)
35. Jager, K.J., Kovesdy, C., Langham, R. et al. (2019). `A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases’, Nephrology Dialysis Transplantation, 34(11), pp.1803-1805. Available at: https://doi.org/10.1093/ndt/gfz174 (Access on June 14, 2023)
36. Jaikumkao, K., et al. 2017. `The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes’, Biomedicine & Pharmacotherapy, 94, pp.176-187. Available at: https://doi.org/10.1093/ndt/gfz174 (Access on June 11, 2023)
37. Karagiannis, T., Tsapas, A., Athanasiadou, E. et al. (2021). `GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis’, Diabetes Clinical Practice. 2021 Apr; 174:108737. Available at: https://doi.org/10.1016/j.diabres.2021.108737. PMID: 33705820. (Access on May 23, 2023)
38. Kanie, T., Mizuno, A., Takaoka, Y. et al. (2021). `DPP4 inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors for people with cardiovascular disease: a network meta‐analysis’, Cochrane Database of Systematic Reviews. Available at: https://doi.org/10.1002/14651858.CD013650.pub2 (Access on June 03, 2023)
39. Kawai, Y., Uneda, K., Yamada, T. et al. (2022). `Comparison of effects of SGLT-2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in T2DM patients with/without albuminuria: a systematic review and network meta-analysis’, Diabetes Research and Clinical Practice, 183, p.109146. Available at: https://doi.org/10.1016/j.diabres.2021.109146 (Access on May 23, 2023)
40. KDIGO (2022). `Clinical Practice Guidelines for Diabetes Management in CKD’, Kidney Int. 2022; 102(4S):S1-S123. Available at: https://doi.org/10.1016/j.kint.2022.06.008 (Access on June 03, 2023)
41. Yau, K., Dharia, A., Alrowiyti, I. et al. (2022). `Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations’, Kidney international reports, 7(7), pp.1463-1476. Available at: https://doi.org/10.1016/j.ekir.2022.04.094 (Access on June 14, 2023)
42. Khoury, C.C., Chen, S., and Ziyadeh, F.N. (2020). `Pathophysiology of diabetic nephropathy’, Chronic Renal Disease (pp. 279-296). Available at: https://doi.org/10.1016/B978-0-12-815876-0.00019-X (Access on June 03, 2023)
43. Kluger, A.Y., Tecson, K., Lee, A.Y. et al. (2019). ‘Class effects of SGLT2 inhibitors on cardiorenal outcomes’, Cardiovascular diabetology, 18, pp.1-13. Available at: https://doi.org/10.1186/s12933-019-0903-4 (Access on June 11, 2023)
44. Kristensen, S.L., Roth, R., Jhund, P.S. et al. (2019). `Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials’, The Lancet Diabetes & Endocrinology, 7(10), pp.776-785. Available at: https://doi.org/10.1016/S2213-8587(19)30249-9 (Access on June 03, 2023)
45. Fu, H., Liu, S., Bastacky, S.I. et al. (2019). `Diabetic kidney diseases revisited: A new perspective for a new era’, Molecular metabolism, 30, pp.250-263. Available at: https://doi.org/10.1016/j.molmet.2019.10.005 (Access on June 03, 2023)
46. Li, J., Neal, B., Perkovoc, V. et al. (2020). `Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes’, Kidney International, 98(3), pp.769-777. Available at: https://doi.org/10.1016/j.kint.2020.04.051 (Access on May 23, 2023)
47. Li, X., Song, Y., Guo, T. et al. (2022). `Effect of glucagon-like peptide 1 receptor agonists on the renal protection in patients with type 2 diabetes: A systematic review and meta-analysis’, Diabetes & Metabolism, p.101366. Available at: https://doi.org/10.1016/j.diabet.2022.101366 (Access on May 23, 2023)
48. Lo, C., Toyama, T., Wang, Y. et al. (2018). `Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease’, Cochrane database of systematic reviews. Available at: https://doi.org/10.1002/14651858.CD011798.pub2 (Access on June 03, 2023)
49. Maddaloni, E., Cavallari I., La Porta, Y. et al. (2023). `Impact of baseline kidney function on the effects of SGLT2 inhibitors on kidney and HF: A systematic review and meta‐analysis of randomized controlled trials’, Diabetes, Obesity, and Metabolism, 25(5), pp.1341-1350. Available at: https://doi.org/10.1111/dom.14986 (Access on May 12, 2023)
50. Mann JFE, Ørsted DD., Brown-Frandsen, K. et al. (2017). `Liraglutide and renal outcomes in type 2 diabetes’, New England Journal of Medicine. 2017;377(9):839-848`. Available at: https://doi.org/10.1056/NEJMoa1616011. PMID: 28854085. (Access on May 12, 2023)
51. Marso, S.P., Daniels, G.H., Brown-Frandsen, K. et al. (2016). `Liraglutide and cardiovascular outcomes in type 2 diabetes’, New England Journal of Medicine, 375(4), pp.311-322. Available at: https://doi.org/10.1056/NEJMoa1603827 (Access at May 12, 2023)
52. Marso, S.P., Stephen, C. B., Consoli, A. et al. (2016). `Semaglutide and cardiovascular outcomes in patients with type 2 diabetes’, New England Journal of Medicine, 375(19), pp.1834-1844. Available at: https://doi.org/10.1056/NEJMoa1607141 (Access on May 12, 2023)
53. Margonato, D., Galati, G., Mazzetti, S. et al. (2021). `Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors’, Heart failure reviews, 26, pp.337-345. Available at: https://doi.org/10.1007/s10741-020-10024-2 (Access on June 14, 2023)
54. McGuire, D.K., Zinman, B., Inzucchi, S. et al. (2020). `Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial’, The Lancet Diabetes & Endocrinology, 8(12), pp.949-959. Available at: https://doi.org/10.1016/S2213-8587(20)30344-2 (Access on May 12, 2023)
55. McGuire, D.K., D’Alessio, D., Nicholls, S.J. et al. (2022). `Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes’, Cardiovascular Diabetology, 21(1), pp.1-9. Available at: https://doi.org/10.1186/s12933-022-01601-w (Access on May 12, 2023)
56. Milder, T.Y., Stoker, S., Baysari, M. et al. (2021). `Prescribing of SGLT2 inhibitors in primary care: A qualitative study of General Practitioners and Endocrinologists’, Diabetes Research and Clinical Practice, 180, p.109036. Available at: https://doi.org/10.1016/j.diabres.2021.109036 (Access on June 14, 2023)
57. Mima, A. (2022). `A narrative review of diabetic kidney disease: previous and current evidence-based therapeutic approaches’, Advances in therapy, 39(8), pp.3488-3500. Available at: https://doi.org/10.1007/s12325-022-02223-0 (Access on May 07, 2023)
58. Mosenzon, O., Wiviott, S.D., Heerspink, H.J.L et al. (2021). `The effect of dapagliflozin on albuminuria in DECLARE-TIMI 58’, Diabetes Care, 44(8), pp.1805-1815. https://doi.org/10.2337/dc21-0076 (Access on June 14, 2023)
59. Mosterd, C.M., Bjornstad, P., and van Raalte. (2020). `Nephroprotective effects of GLP-1 receptor agonists: where do we stand’, Journal of Nephrology, 33, pp.965-975. Available at: https://doi.org/10.1007/s40620-020-00738-9 (Access on June 14, 2023)
60. Nagahisa, T. and Saisho, Y. (2019). `Cardiorenal protection: the potential of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes’, Diabetes Therapy, 10(5), pp.1733-1752. Available at: https://doi.org/10.1007/s13300-019-00680-5 (Access on June 14, 2023)
61. Nagasu, H., Yano, Y., Kanegae, H. et al. (2021). `Kidney outcomes associated with SGLT2 inhibitors versus other glucose-lowering drugs in real-world clinical practice: the Japan chronic kidney disease database’, Diabetes Care, 44(11), pp.2542-2551. Available at: https://doi.org/10.2337/dc21-1081 (Access on May 23, 2023)
62. Nathan, D.M., Buse, J.B., Davidson, M.B. et al. (2009). `Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy’, Diabetes care, 32(1), pp.193-203. Available at: https://doi.org/10.2337/dc08-9025 (Access on June 14, 2023)
63. Nauck, M.A., Meier, J., Mathew, A. et al. (2017). `Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors’, Circulation, 136(9), pp.849-870. Available at: https://doi.org/10.1161/CIRCULATIONAHA.117.028136 (Access on June 14, 2023)
64. Neuen, B.L., Young, T., Heerspink, H. J.L. et al. (2019). `SGLT2 inhibitors for the prevention of kidney failure in patients with T2DM: a systematic review and meta-analysis’, The Lancet Diabetes & Endocrinology, 7(11), pp.845-854. Available at: https://doi.org/10.1016/S2213-8587(19)30256-6 (Access on May 07, 2023)
65. Nguyen, B.N., Nguyen, Le., Mital, S. et al. (2023). `Comparative Efficacy of SGL2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease and Type 2 Diabetes: A Systematic Review and Network Meta‐Analysis’, Diabetes, Obesity and Metabolism’. Available at: https://doi.org/10.1111/dom.15009 (Access on May 12, 2023)
66. Neal, B., Perkovic, V., Mahaffey, K.W. et al. (2017). `Canagliflozin and cardiovascular and renal events in T2DM’, New England Journal of Medicine, 377(7), pp.644-657’. Available at: https://doi.org/10.1056/NEJMoa1611925. (Access on May 07, 2023)
67. Ninčević, V., Omanović Kolarić, T., Roguljić, H. et al. (2019). `Renal benefits of SGLT 2 inhibitors and GLP-1 receptor agonists: evidence supporting a paradigm shift in the medical management of type 2 diabetes’, International Journal of Molecular Sciences, 20(23), p.5831.Available at: https://doi.org/10.3390/ijms20235831
68. Packer, M., Butler, J., Filippatos, G. S. et al. (2019). `Evaluation of the effect of SGLT2 2 inhibitors with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial’, European Journal of heart failure, 21(10), pp.1270-1278’. Available at: https://doi.org/10.1002/ejhf.1536 (Access on May 12, 2023)
69. Palmer, S.C., Tendal, B., Mustafa, R.A. et al. (2021). `SGLT-2 inhibitors and GLP-1 receptor agonists for type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials’, The BMJ 372’. Available at: https://doi.org/10.1136/bmj.m4573 (Access on May 07, 2023)
70. Patoulias, D., Papadopoulos, C., Karagiannis, A. et al. (2022). `Meta-analysis assessing the impact of previous heart failure and chronic kidney disease on the cardiovascular efficacy of glucagon-like peptide-1 receptor agonists’, American Journal of Cardiology, 167, pp.165-167. Available at: https://doi.org/10.1016/j.amjcard.2021.12.040 (Access on June 15, 2023)
71. Perkovic, V., Jardine, M.J., Neal, B. et al. (2019). `Canagliflozin and renal outcomes in type 2 diabetes and nephropathy’, New England Journal of Medicine, 380(24), pp.2295-2306. Available at: https://doi.org/10.1056/NEJMoa1811744. (Access on May 07, 2023)
72. Porzsolt, F., Wiedemann, F., and Becker, S.I. et al. (2019). `Inclusion & exclusion criteria and the problem of describing homogeneity of the study population in clinical trials’, BMJ evidence-based medicine, 24(3), pp.92-94. Available at: http://dx.doi.org/10.1136/bmjebm-2018-111115 (Access on May 07, 2023)
73. Qiu M., Liang, D., Xu-Bin, W. et al. (2021). `Comparative efficacy of GLP-1 receptor agonists and SGLT2 Inhibitors for prevention of major adverse cardiovascular events in T2DM’, A network meta-analysis; Journal of Cardiovascular Pharmacology. 2021 Jan 1;77(1):34-37`. Available at: doi:10.1097/FJC.00000000000916. PMID: 33136765. (Access on May 07, 2023)
74. Rangaswami, J., Bhalla, V., de Boer, I. H. et al. (2020). `Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American Heart Association’, Circulation, 142(17), pp. e265-e286`. Available at: https://doi.org/10.1161/CIR.0000000000000920. (Access on March 30, 2023)
75. Ravindran, S. and Munusamy, S., (2022). `Reno-protective mechanisms of SGLT2 inhibitors against the progression of diabetic kidney disease’, Journal of cellular physiology, 237(2), pp.1182-1205. Available at: https://doi.org/10.1002/jcp.30621 (Access on March 30, 2023)
76. Rossing, P., Caramori, M.L., Chan, J.C.N. et al. (2022). `Executive summary of the KDIGO 2022. Clinical practice guideline for diabetes management in CKD: an update based on rapidly emerging new evidence’, Kidney International, 102(5), pp.990-999. Available at: https://doi.org/10.1016/j.kint.2022.06.013 (Access on June 14, 2023)
77. Sarafidis, P., Ferro, C.J., Morales, E. et al. (2019). `SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA’, Nephrology Dialysis Transplantation, 34(2), pp.208-230. Available at: https://doi.org/10.1093/ndt/gfy407 (Access on June 14, 2023)
78. Sattar N., Lee, M., Kristensen, S.L. et al. (2021). `Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with T2DM: a systematic review and meta-analysis of RCTs’, Lancet Diabetes Endocrinology 2021;9:653–662. Available at: https://doi.org/10.1016/S2213-8587(21)00203-5 (Access on May 07, 2023)
79. Scheen, A.J. (2018). “Cardiovascular outcome studies in type 2 diabetes: comparison between SGLT2 inhibitors and GLP-1 receptor agonists’, Diabetes Research and Clinical Practice, 143, pp.88-100. Available at: https://doi.org/10.1016/j.diabres.2018.06.008 (Access on May 07, 2023)
80. Scheen, A.J. (2019). “Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes’, Diabetes & metabolism, 45(2), pp.110-121. Available at: https://doi.org/10.1016/j.diabet.2018.10.003 (Access on June 15, 2023)
81. Shaman, A.M., Bain. S., Bakris. G. et al. (2022). `Effect of the glucagon-like peptide-1 receptor agonists Semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER’, Circulation, 145(8), pp.575-585. Available at: https://doi.org/10.1161/CIRCULATIONAHA.121.055459 (Access on June 15, 2023)
82. Shami, D., Sousou, J., Batarseh, E. et al. (2023). `The roles of Glucagon-Like Peptide 1 (GLP-1) receptor agonists and Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in decreasing the occurrence of adverse cardiorenal events in patients with Type 2 Diabetes’, Cureus, 15(1). Available at: https://doi.org/10.7759/cureus.33484 (Access on May 07, 2023)
83. Shepard, B.D. and Ecelbarger, C.M. (2022). `SGLT2 inhibitors and GLP-1 RAs: newer therapies in whole-body glucose stabilization’, Seminars in Nephrology (Vol. 41, No. 4, pp. 331-348). WB Saunders. Available at: https://doi.org/10.1016/j.semnephrol.2021.06.005 (Access on June 15, 2023)
84. Sloan, L.A. (2019). `Review of glucagon‐like peptide‐1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects’, Journal of diabetes, 11(12), pp.938-948. Available at: https://doi.org/10.1111/1753-0407.12969 (Access on March 30, 2023)
85. Thomas, M.C. and Cherney, D.Z. (2018). `The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure’, Diabetologia, 61, pp.2098-2107. Available at: https://doi.org/10.1007/s00125-018-4669-0 (Access on June 15, 2023)
86. Tuttle KR., Brosius, F., Cavender, M. et al. (2021). `SGLT2 Inhibition for CKD and cardiovascular disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation’, Diabetes. 2021 Jan;70(1):1-16. Available at: https://doi 10.2337/dbi20-0040.PMID: 33106255 (Access on May 07, 2023)
87. Tuttle KR., Lakshmanan, M., Rayner, B. et al. (2018). `Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7)’, Lancet Diabetes Endocrinol. 2018 Apr;6(4):605-617. Available at: https://doi: 10.1016/S2213-8587(18)30051-2. PMID: 29502976. (Access on March 30, 2023)
88. Uneda, K., Kawai, Y., Yamada, T. et al. (2022). `Japanese traditional Kampo medicine bofutsushosan improves body mass index in participants with obesity: A systematic review and meta-analysis’, Plos one, 17(4), p. e0266917. Available at: https://doi.org/10.1371/journal.pone.0266917(Access on March 30, 2023)
89. Vallon, V. and Thomson, S.C. (2017). `Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition’, Diabetologia, 60(2), pp.215-225. Available at: https://doi.org/10.1007/s00125-016-4157-3 (Access on June 15, 2023)
90. van Baar, M.J., Van Ruiten, C., Muskiet, M. et al. (2018). `SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in T2DM management’, Diabetes care, 41(8), pp.1543-1556. Available at: https://doi.org/10.2337/dc18-0588 (Access on March 30, 2023)
91. Wanner C., Inzucchi, S. E., Lachin, J.M. et al. (2016). `Empagliflozin and progression of kidney disease in Type 2 Diabetes’, N Engl J Med. 2016 Jul 28; 375(4):323-34. Available at: https://doi.org/10.1056/NEJMoa1515920. PMID: 27299675. (Access on May 07, 2023)
92. Wheeler, D.C., Toto, R.D., Stefansson, B.V. et al. (2020). `The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics’, Nephrology Dialysis Transplantation, 35(10), pp.1700-1711. Available at: https://doi.org/10.1016/j.kint.2021.03.033 (Access on May 07, 2023)
93. Wei XB.,Wei, W, Ding, L. et al. (2021). `Comparison of the effects of 10 GLP-1 RAs and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in T2DM: A network meta-analysis of large randomized trials’, Prim Care Diabetes. 2021. Apr;15(2): 208-211. Available at: https://doi: 10.1016/j.pcd.2020.08.017. (Access on March 13, 2023)
94. Williams, D.M., Nawaz, A. and Evans, M. et al. (2020). `Renal outcomes in type 2 diabetes. A review of cardiovascular and renal outcome trials’, Diabetes Therapy, 11(2), pp.369-386. Available at: https://doi.org/10.1007/s13300-019-00747-3 (Access on May 07, 2023)
95. Wiviott, S.D., Raz, Itamar., Bonaca, M.P. et al. (2019). `Dapagliflozin and cardiovascular outcomes in type 2 diabetes’, New England Journal of Medicine, 380(4), pp.347-357. Available at: https//doi.org/10.1056/NEJMoa1812389 (Access on March 30, 2023)
96. Yamada, T., Wakabayashi, M., Bhalla, A. et al. (2021). `Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis’, Cardiovascular diabetology, 20(1), pp.1-13. Available at: https://doi.org/10.1186/s12933-020-01197-z (Access on March 13, 2023)
97. Yang, S., He, W., Zhao, Lu. (2022). `Association between use of SGLT2 inhibitors, GLP-1 receptor agonists, and dipeptidyl peptidase 4 inhibitors with kidney outcomes in patients with type 2 diabetes: A systematic review and network meta-analysis’, Plos, one, 17(4), p. e0267025. Available at: https://doi.org/10.1371/journal.pone.0267025 (Access on June 15, 2023)
98. Yang, Q., Lang, Y., Yang, W. et al. (2023). `Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: a systematic review and network meta-analysis of randomized controlled trials’, Diabetes Research and Clinical Practice, p.110592. Available at: https://doi.org/10.1016/j.diabres.2023.110592 (Access on May 07, 2023)
99. Zelniker, T.A., Wiviott, S.D., Raz, I. et al. (2019). `Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus: systematic review and meta-analysis of cardiovascular outcomes trials’, Circulation, 139(17), pp.2022-2031. Available at: https://doi.org/10.1161/CIRCULATIONAHA.118.038868 (Access on March 13, 2023)
100. Zelniker, T.A., Wiviott, S.D., Raz, I. et al. (2019). `SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials’, The Lancet, 393(10166), pp.31-39. Available at: https://doi.org/10.1016/S0140-6736(18)32590-X (Access on March 13, 2023)
101. Zhang, Y., Jiang, L., Wang, J. et al. (2022). `Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease’, Cardiovascular diabetology, 21(1), pp.1-23. Available at: https://doi.org/10.1186/s12933-022-01676-5 (Access on March 30, 2023)
102. Zheng, S.L., Roddick, A.J., Aghar-Jaffar, R. et al. (2018). `Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis’, Jama, 319 (15), pp.1580-1591. Available at: https://doi.org/10.1001/jama.2018.3024 (Access on March 13, 2023)
Article Sidebar
Published
Jun 7, 2024
Article Details
How to Cite
Iqbal Saeed Shaikh, Kumayl Abbas Meghji, Tariq Feroz Memon, Sadia Kazi, Areej Muhammad, & Urooj Mannan Shaikh. (2024). RENAL PROTECTIVE COMPARISON BETWEEN SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS VERSUS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS: A SYSTEMATIC REVIEW. Journal of Population Therapeutics and Clinical Pharmacology, 31(6), 459-478. https://doi.org/10.53555/jptcp.v31i6.6423
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Author Biographies
Iqbal Saeed Shaikh
Ambulatory Health Services, UAE
Kumayl Abbas Meghji
Department of Physiology, Isra University, Hyderabad
Tariq Feroz Memon
Department of Community Medicine and Public Health Sciences, LUMHS, Jamshoro..
Sadia Kazi
Department of Pharmacology, Isra University, Hyderabad.
Areej Muhammad
Department of Internal Medicine, LUMHS, Jamshoro.
Urooj Mannan Shaikh
Isra University, Hyderabad.
How to Cite
Iqbal Saeed Shaikh, Kumayl Abbas Meghji, Tariq Feroz Memon, Sadia Kazi, Areej Muhammad, & Urooj Mannan Shaikh. (2024). RENAL PROTECTIVE COMPARISON BETWEEN SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS VERSUS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS: A SYSTEMATIC REVIEW. Journal of Population Therapeutics and Clinical Pharmacology, 31(6), 459-478. https://doi.org/10.53555/jptcp.v31i6.6423